Hempling R E, Piver M S, Eltabbakh G H, Recio F O
Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Am J Clin Oncol. 1998 Oct;21(5):447-51. doi: 10.1097/00000421-199810000-00005.
The purpose of this study was to determine if tumor estrogen receptor (ER) or progesterone receptor (PR) status were significant prognostic variables of survival and progression-free survival among patients with International Federation of Gynecology and Obstetrics (FIGO) stage III and IV epithelial ovarian cancer. Tumor steroid receptor status was evaluated among 67 consecutive patients who underwent primary surgery from June 1983 through September 1990. Characteristics of receptor-negative and receptor-positive populations were compared by chi-square analysis. Univariate and multivariate analyses were used to identify variables prognostic of survival and progression-free survival. Fifty-one of 67 patients (76.1%) had ER-positive tumors and 31 (46.3%) patients had PR-positive tumors. Significant differences between receptor-positive and receptor-negative populations were not observed. Neither univariate nor multivariate analysis identified ER or PR status as significant prognostic variables of survival (p = 0.93 and p = 0.06, respectively). Progesterone receptor-positive status was a significant prognostic variable of progression-free survival in both univariate (p = 0.03) and multivariate (p = 0.04) analyses even after adjustment for residual disease and patient age. Estrogen receptor status was not a significant prognostic indicator of progression-free survival in either univariate or multivariate analyses. Progesterone receptor-positive tumor status is shown to be an independent prognostic variable of improved progression-free survival among patients with advanced epithelial ovarian cancer.
本研究的目的是确定肿瘤雌激素受体（ER）或孕激素受体（PR）状态是否为国际妇产科联盟（FIGO）III期和IV期上皮性卵巢癌患者生存及无进展生存的显著预后变量。对1983年6月至1990年9月期间连续接受初次手术的67例患者的肿瘤类固醇受体状态进行了评估。通过卡方分析比较受体阴性和受体阳性人群的特征。采用单因素和多因素分析来确定生存及无进展生存的预后变量。67例患者中有51例（76.1%）肿瘤ER阳性，31例（46.3%）患者肿瘤PR阳性。未观察到受体阳性和受体阴性人群之间的显著差异。单因素和多因素分析均未将ER或PR状态确定为生存的显著预后变量（p值分别为0.93和0.06）。即使在对残留疾病和患者年龄进行调整后，孕激素受体阳性状态在单因素分析（p = 0.03）和多因素分析（p = 0.04）中均为无进展生存的显著预后变量。雌激素受体状态在单因素或多因素分析中均不是无进展生存的显著预后指标。孕激素受体阳性肿瘤状态被证明是晚期上皮性卵巢癌患者无进展生存改善的独立预后变量。
